<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05047159</url>
  </required_header>
  <id_info>
    <org_study_id>2020-74</org_study_id>
    <nct_id>NCT05047159</nct_id>
  </id_info>
  <brief_title>The Role of Neuromodulation Technique In Depression Disorder</brief_title>
  <official_title>Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Mental Health Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Mental Health Center</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to explore the efficacy, safety and long-term effects of common and available&#xD;
      non-invasive neuromodulation techniques in the treatment of depression, and to provide a data&#xD;
      basis for the establishment of individualized treatment and efficacy prediction models. 450&#xD;
      patients will be enrolled and randomly assigned to five different treatments.&#xD;
      Psychopathological assessment will be performed in both acute and maintenance phases of&#xD;
      treatment with the Hamilton Depression Rating Scale, the Hamilton Anxiety Rating Scale, and&#xD;
      the Patient Health Questionaire-9, the Sheehan Disability Scale, the Vascular Quality of&#xD;
      Life-6 Questionnaire respectively.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 1, 2021</start_date>
  <completion_date type="Anticipated">June 30, 2024</completion_date>
  <primary_completion_date type="Anticipated">March 30, 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>the change of the HAMD-17 score</measure>
    <time_frame>baseline, and 1, 2, 4, 8, 12, 24, 36, 48 weeks.</time_frame>
    <description>the change of HAMD-17 score between baseline and after treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>remission rate</measure>
    <time_frame>12, 24, 36, 48 weeks.</time_frame>
    <description>HAMD-17 total score ≤ 7 after treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>response rate</measure>
    <time_frame>12, 24, 36, 48 weeks.</time_frame>
    <description>a reduction rate of HAMD-17 score ≥ 50% from baseline after treatment.</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">450</enrollment>
  <condition>Depressive Disorder, Major</condition>
  <arm_group>
    <arm_group_label>drug therapy group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug: drug therapy There is no restriction on the choice of therapeutic drugs.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>drug therapy combined with repetitive transcranial magnetic stimulation (rTMS) group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Device: rTMS Stimulation will be performed for 20 working days once a day (4 weeks). Extend course to 30 sessions (6 weeks) in responders who have not achieved symptom remission.&#xD;
Frequency: 10Hz; Intensity: 110% RMT; Coil-type: F8; Sessions-pulse: 3000; Site: the left dorsolateral prefrontal cortex.&#xD;
Drug: drug therapy There is no restriction on the choice of therapeutic drugs.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>drug therapy combined with light therapy group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Device: light therapy Active 10,000-lux fluorescent white light box for 30 min/d in the early morning for 6 weeks.&#xD;
Drug: drug therapy There is no restriction on the choice of therapeutic drugs.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>drug therapy combined with electroconvulsive therapy (ECT) group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Device: ECT The electrode placements are bifrontal (BF); the electrical intensity is 1.5 to 2.0 times the seizure threshold (ST); 3 times per week.&#xD;
Drug: drug therapy There is no restriction on the choice of therapeutic drugs.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>drug therapy combined with magnetic seizure therapy (MST) group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Device: MST A coil placement at the vertex (i.e., Cz in 10-20 electroencephalogram [EEG] system) with a frequency of stimulation of 100 Hz, pulse width of 0.2 to 0.4 ms, and stimulation duration of 10 seconds; 2 times per week.&#xD;
Drug: drug therapy There is no restriction on the choice of therapeutic drugs.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>rTMS</intervention_name>
    <description>Stimulation will be performed for 20 working days once a day (4 weeks). Extend course to 30 sessions (6 weeks) in responders who have not achieved symptom remission.&#xD;
Frequency: 10Hz; Intensity: 110% RMT; Coil-type: F8; Sessions-pulse: 3000; Site: the left dorsolateral prefrontal cortex.</description>
    <arm_group_label>drug therapy combined with repetitive transcranial magnetic stimulation (rTMS) group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>light therapy</intervention_name>
    <description>Active 10,000-lux fluorescent white light box for 30 min/d in the early morning for 6 weeks.</description>
    <arm_group_label>drug therapy combined with light therapy group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>ECT</intervention_name>
    <description>The electrode placements are bifrontal (BF); the electrical intensity is 1.5 to 2.0 times the seizure threshold (ST); 3 times per week.</description>
    <arm_group_label>drug therapy combined with electroconvulsive therapy (ECT) group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>MST</intervention_name>
    <description>A coil placement at the vertex (i.e., Cz in 10-20 electroencephalogram [EEG] system) with a frequency of stimulation of 100 Hz, pulse width of 0.2 to 0.4 ms, and stimulation duration of 10 seconds; 2 times per week.</description>
    <arm_group_label>drug therapy combined with magnetic seizure therapy (MST) group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>drug therapy</intervention_name>
    <description>There is no restriction on the choice of therapeutic drugs.</description>
    <arm_group_label>drug therapy combined with electroconvulsive therapy (ECT) group</arm_group_label>
    <arm_group_label>drug therapy combined with light therapy group</arm_group_label>
    <arm_group_label>drug therapy combined with magnetic seizure therapy (MST) group</arm_group_label>
    <arm_group_label>drug therapy combined with repetitive transcranial magnetic stimulation (rTMS) group</arm_group_label>
    <arm_group_label>drug therapy group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age 18-60;&#xD;
&#xD;
          2. Meet the DSM-IV &quot;major Depressive Episode&quot; diagnostic criteria and are currently in&#xD;
             the depressive episode (MDE) stage;&#xD;
&#xD;
          3. The 17-item Hamilton Depression Scale (HAMD-17) score was &gt; 17, and the HAMD-17 item 1&#xD;
             (depression) score was ≥2;&#xD;
&#xD;
          4. Failure to respond adequately to at least one of the new antidepressants (including a&#xD;
             HAMD-17 reduction rate of less than 50% and an intolerant drug side effect);&#xD;
&#xD;
          5. Junior high school education or above, with sufficient audio-visual understanding of&#xD;
             the research content, and signed the informed consent;&#xD;
&#xD;
          6. If drug therapy is used at the same time, the medication regimen should remain&#xD;
             unchanged at least 4 weeks before the follow-up group, and continue to remain&#xD;
             unchanged during the neurological intervention in the acute phase;&#xD;
&#xD;
          7. Right-handed.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Schizophrenia, or psychotic symptoms unrelated to depression, bipolar disorder, eating&#xD;
             disorder, etc.;Personality disorders and mental retardation;Patients with depression&#xD;
             caused by physical diseases;&#xD;
&#xD;
          2. Suffering from the following serious diseases:History of brain injury or&#xD;
             cerebrovascular accident, narrow-angle glaucoma, epilepsy, myocardial infarction,&#xD;
             unstable angina pectoris, congestive heart failure, severe cirrhosis, acute and&#xD;
             chronic renal failure, severe diabetes, aplastic anemia,Moderate to severe&#xD;
             malnutrition and other serious neurological, heart, liver, kidney, endocrine, blood&#xD;
             system and other physical diseases or diseases that may interfere with the study&#xD;
             (abnormal index is more than 2 times the normal value);&#xD;
&#xD;
          3. Patients with metal implants or electronic instruments (such as embedded intracranial&#xD;
             electrodes, cochlea, medical pump, etc.), photosensitive dermatitis and other skin&#xD;
             diseases or other contraindications in the body;&#xD;
&#xD;
          4. Intracranial mass, cerebral infarction, increased intracranial pressure, or other&#xD;
             active central nervous system disease, including epilepsy;Dementia, delirium, memory&#xD;
             loss or other cognitive disorders;Brain trauma that increases the risk of seizures;&#xD;
&#xD;
          5. Severe drug allergic reaction;&#xD;
&#xD;
          6. Pregnant, lactating or planning to become pregnant;&#xD;
&#xD;
          7. Substance abuse (excluding caffeine and nicotine) in the past 3 months;&#xD;
&#xD;
          8. Received rTMS, tDCS, tACS, light therapy, ECT, MST, DBS therapy in the past 3 months;&#xD;
&#xD;
          9. Serious suicide attempt (hamD-17 item 3 &quot;suicide&quot; score ≥3);&#xD;
&#xD;
         10. Refuse to sign the informed consent.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Shanghai Mental Health Center</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200030</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 9, 2021</study_first_submitted>
  <study_first_submitted_qc>September 14, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 16, 2021</study_first_posted>
  <last_update_submitted>September 21, 2021</last_update_submitted>
  <last_update_submitted_qc>September 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

